Insight Molecular Diagnostics Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
| ONCOCYTE CORPORATION | |
| Date: March 24, 2025 | By: /s/ Joshua Riggs |
|---|---|
| Joshua Riggs | |
| President and Chief Executive Officer(Principal Executive Officer) | |
| Date: March 24, 2025 | By: /s/ Andrea James |
| Andrea James | |
| Chief Financial Officer(Principal Financial Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Joshua Riggs | President and Chief Executive Officer and Director | March 24, 2025 |
| JOSHUA RIGGS | (Principal Executive Officer) | |
| /s/ Andrea James | Chief Financial Officer | March 24, 2025 |
| ANDREA JAMES | (Principal Financial Officer) | |
| /s/ James Liu | Vice President Accounting, Controller, Treasurer and Principal Accounting Officer | March 24, 2025 |
| JAMES LIU | (Principal Accounting Officer) | |
| /s/ Andrew Arno | Director | March 24, 2025 |
| ANDREW ARNO | ||
| /s/ Andrew J. Last | Director | March 24, 2025 |
| ANDREW J. LAST | ||
| /s/ Louis E. Silverman | Director | March 24, 2025 |
| LOUIS E. SILVERMAN | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.